chrisvoncsefalvay/vaers-outcomes huggingface dataset:
she usually have body and muscle ache after getting the vaccine; she usually have body and muscle ache after getting the vaccine; For the first two she felt a little tired; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 Immunization, reaction(s): "For the first two she felt a little tired", "she usually have body and muscle ache after getting the vaccine", "she usually have body and muscle ache after getting the vaccine". The following information was reported: PAIN (non-serious), MYALGIA (non-serious), outcome "unknown" and all described as "she usually have body and muscle ache after getting the vaccine"; FATIGUE (non-serious), outcome "unknown", described as "For the first two she felt a little tired".  Additional Information: It was reported that patient usually had body and muscle ache after getting the vaccine. For the first two she felt a little tired. Case was reported as non-serious.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Information has been received from a physician concerning a 70 year old female who on 21-OCT-2006 was vaccinated intramuscularly with a 0.5 mL dose of Pneumovax 23 (Lot # 651404/0352F).  On 21-OCT-2006, a few hours later, the patient developed redness, swelling and soreness at injection site of right arm.  The patient sought medical attention.  The physician recommended ice compresses and BENADRYL.  The patient was re-examined on 23-OCT-2006 which revealed redness and swelling resolved but continuing mild soreness.  The physician added that the patient has had Pneumovax 23 "multiple times" in the past without difficulty.  Additional information has been requested.
7 days after vaccination she experienced swelling and redness beneath vaccination site and over prior BCG scar in the left arm.  Redness grew larger and symptoms are still present 6 days later.  No fever, chills or suspicion of cellulitis
Beginning the day after the vaccine I experienced the following for the next 36 hours: Sore arm, painful to movement and to touch,at site of injection, chills, fever, body aches, fatigue, stomach pain, abdominal discomfort diarrhea. Seventy-two hours after the vaccine, all symptoms except the diarrhea had resolved with the diarrhea resolving on 2/17/2019.
This case was reported by a consumer via call center representative and described the occurrence of exhaustion in a 60-year-old male patient who received SHINGRIX for prophylaxis. On 13th March 2019, the patient received the 2nd dose of SHINGRIX. On 14th March 2019, 1 days after receiving SHINGRIX, the patient experienced exhaustion, unable to walk, facial rash, nausea, lethargy and feeling unwell. On an unknown date, the outcome of the exhaustion, unable to walk, facial rash, nausea, lethargy and feeling unwell were not recovered/not resolved. It was unknown if the reporter considered the exhaustion, unable to walk, facial rash, nausea, lethargy and feeling unwell to be related to SHINGRIX. Additional details were provided as follows: The case was reported by the patient for himself. The patient was not feeling right in the morning of 14th March 2019, he felt exhausted and couldn't even walk. He was feeling progressively worse, he got a rash on the forehead and the right side of face, had nausea and felt lethargic. On 18th March 2019, the patient felt better and was fine on 19th March 2019 but the symptoms came back on 20th March 2019. The patient had all the symptoms at the time of reporting. The patient did not provide the consent to follow up.
pt recv vax;episodes of shaking w/ eyes rolled up;no LOC;some breath holding;at ofc;tests nl;next day had sz;@ med ctr, abnl EEG;on phenobarbital;dx sz disorder;
It was reported that a 71 year old male pt received a Yellow fever vaccination on 10/04/2002. It was reported that the onset date for symptoms was 10/10/2001. Illness occurred on day 7. Pt had specific IgM directed against YF in the CSF which may suggest CNS infection with 17D. Testing to date has been inconclusive and some cultures are still pending.
Initial report received from a healthcare professional on 11 September 2013. A patient whose gender, age at the time of event, medical history and concomitant medications were not reported, had received a dose of DIPHTHERIA AND TETANUS TOXOIDS vaccine (unknown manufacturer, lot number, dose number, route and anatomical site of administration were not reported) on an unspecified date. On an unspecified date, the patient developed a bad reaction (unspecified). Lab details and corrective treatment details were not provided. At the time of this report, the outcome was not reported. At the time of this report, the outcome was not reported. List of documents held by sender: none. Follow up information received from a healthcare professional on 21 October 2013 stating no further information available.
BROKEN HIP; HAIRLINE FRACTURE IN ARM; FELL; PAIN IN BACK OF CALF; BLOOD CLOT; MILDLY SORE ARM AROUND INJECTION SITE; This spontaneous report received from a consumer concerned a 67 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included shoulder pain. The patient did not have a history of blood clots, and was not pregnant at the time of vaccination. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1816022 expiry: Unknown) dose was not reported, 1 total, administered on 09-MAY-2021, about 17:00 pm, to left arm for prophylactic vaccination. Concomitant medications included ibuprofen for shoulder pain.  On an unspecified date in MAY-2021, the patient had mildly sore arm around injection site which had resolved (Unspecified date). On 11-MAY-2021, two days after receiving the vaccine, about 8:00 am in the morning, the patient fell and broke her hip and arm. The hip needed a rod and the patient had surgery to repair the hip by 17:00-18:00pm, the arm was a hair-line fracture and the patient was hospitalized.  About a week and a half after the surgery, the patient experienced pain in back of calf, had an ultrasound, and found blood clot. She was put on blood thinners (unknown name). The blood clot was resolving, breaking up and going away. The reporter did not think that blood clot had anything to do with suspect company. On 02-JUN-2021, the patient was discharged from the rehab within the hospital, where she had her surgery and other care. The patient was hospitalized for 23 days. Its marked 3 weeks since she fell, she had very health exercises and does boot camps. The patient could now take 2 steps with walker, could stand up and pivot, go to bathroom by herself, physical therapy would be given at the patient's house, and it is expected that she will make full recovery.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from mildly sore arm around injection site, was recovering from blood clot, and the outcome of fell, broken hip, pain in back of calf and hairline fracture in arm was not reported. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0: 20210605202-Covid-19 vaccine ad26.cov2.-Blood clot ,Broken hip, Hairline fracture in arm, Fell. This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).  20210605202-Covid-19 vaccine ad26.cov2.-Pain in back of calf. This event(s) is labeled per RSI and is therefore considered potentially related.
Information has been received from a pharmD concerning a 59 year old male with no pertinent medical history and no drug reactions/allergies who on 01-OCT-2007 was vaccinated intramuscularly (site not reported) with a dose of pneumococcal 23v polysaccharide vaccine (lot#657526/0555U). On 02-OCT-2007, post vaccination, the patient developed severe pain in the right arm and had trouble moving his arm. The patient rated his pain as 10 out of 10. The pharmD did not know if the patient had been administered pneumococcal 23v polysaccharide vaccine prior to this dose. The patient did receive unspecified medical attention and it is unknown if the patient recovered. This is one of several reports with the same source. Additional information has been requested.
Two days after PNEUMOVAX injection, patient had swelling at site of injection and redness. MD prescribed erythromycin in case of infection.
Bad headache, nausea, fever, body aches, gastrointestinal discomfort, general malaise. Went from perfectly healthy to wanting to curl up in a corner and cry.
This is an instance of breakthrough COVID-19 after which death occurred.   The individual was vaccinated with the Pfizer product on 01/26/2021, 02/16/2021, and 10/28/2021. They presented to emergency department on 05/14/2022 with primary complaints of general weakness, difficulty standing up, and difficulty ambulating. They tested positive for COVID-19 on 05/15/2022 at the hospital. They were found to be experiencing complications of aspiration pneumonia and acute kidney failure.  They remained hospitalized until their death on 05/28/2022.
Pain; Redness; Itchiness; Swelling; This spontaneous case was reported by a patient and describes the occurrence of PAIN (Pain), VACCINATION SITE SWELLING (Swelling), VACCINATION SITE ERYTHEMA (Redness that has slowly spread over arm) and VACCINATION SITE PRURITUS (Itchiness) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced PAIN (Pain), VACCINATION SITE SWELLING (Swelling), VACCINATION SITE ERYTHEMA (Redness that has slowly spread over arm) and VACCINATION SITE PRURITUS (Itchiness). At the time of the report, PAIN (Pain), VACCINATION SITE SWELLING (Swelling) and VACCINATION SITE PRURITUS (Itchiness) outcome was unknown and VACCINATION SITE ERYTHEMA (Redness that has slowly spread over arm) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication and treatment information were not reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Grandmother phoned health department approximately 45 minutes following child's 2nd dose of varicella on 8/15/07.  Stated client had fever of 102F and had vomited.  Grandmother instructed by health department to give child Motrin and take her to MD or ER if symptoms persisted.  Also instructed to call back to the health department.  On August 16th, pm, grandmother called and stated that child had awakened the morning of the 16th with "red rash all over her body", temp of 103, and had been taken to family MD. Dr. prescribed Benadryl 50 mg po every 4 hours x 24 hours and decrease to every 6 hours and to  continue giving child Motrin as needed for fever.  Telephone call to grandmother by health department nurse on 8/17/07 to check on child's progress. Grandmother stated that child has no fever and only a "little rash" on her body.  Stated child "is back to her normal self".
Headache; dizziness; fatigue; chills; body aches; This is a spontaneous report from a contactable other hcp. A 41-year-old non-pregnant female patient received first dose bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: solution for injection, Batch/Lot Number: EN6202; Expiration date was unknown), via an unspecified route of administration, administered in Arm Left on 26Feb2021 12:00 (age at vaccination 41-year-old) as 1ST DOSE, SINGLE for covid-19 immunization. The vaccine facility was other. Medical history included asthma, allergy, depression, ADHD, long haul Covid symptoms, covid-19, known allergies: Cats and mold. Concomitant medications included lisdexamfetamine mesilate (VYVANSE); escitalopram oxalate (LEXAPRO); dienogest, ethinylestradiol (LARISSA); montelukast sodium; budesonide, formoterol fumarate (SYMBICORT). On 26Feb2021 at 19:00, the patient experienced headache, dizziness, fatigue, chills, body aches. Patient reports about the covid vaccine. Patient had no other vaccination in four weeks. Reported that patient had covid prior to vaccination and not tested post vaccination. Patient was not received any treatment. The outcome of event was not recovered.   No follow-up attempts are possible. No further information is expected.
hearing a sound in her ear; acting crazy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 29 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 immunization. The following information was reported: HYPOACUSIS (non-serious), outcome "unknown", described as "hearing a sound in her ear"; ABNORMAL BEHAVIOUR (non-serious), outcome "unknown", described as "acting crazy".  Additional information: Reporter was calling about her 29 year-old daughter who received both doses of the purple cap Pfizer Covid-19 vaccine and now is hearing a sound in her ear that sounds like two microphones put together per reporter's daughter. Reporter denies that it was ringing that she hears and was unsure of what her daughter was hearing. Reporter states that her daughter was acting crazy and asking "us if we can hear it?". Reporter stated that she read somewhere that 10% of the people who receive the Pfizer Covid-19 vaccine have the same complaints and her daughter was one of them but nothing happened to the reporter when she got the Pfizer Covid-19 vaccine. Reporter states that her daughter had not contacted her HCP yet about the above complaints. Reporter also stated during the call that there were people who have side effects from the purple cap Pfizer Covid-19 vaccine and they have to live with the side effects for the rest of their lives. Reporter was asking how long will the above complaints last and what can her daughter do to help her with these complaints? Reporter says that after both doses of the Covid Vaccine her daughter is hearing a sound in her ears, like 2 microphones in her ears. Reporter states that her daughter had them listen to see if they could also hear it; reporter could not hear it. Reporter asks how long should this last?  Follow-up attempts completed. No further information is expected.
No adverse event; Lower-than-authorized dose administered; This spontaneous case was reported by a physician and describes the occurrence of INCORRECT DOSE ADMINISTERED (Lower-than-authorized dose administered) and NO ADVERSE EVENT (No adverse event) in a 4-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 215K22A) for COVID-19 prophylaxis.     No Medical History information was reported.  On 09-Aug-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 09-Aug-2023, after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced INCORRECT DOSE ADMINISTERED (Lower-than-authorized dose administered). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, INCORRECT DOSE ADMINISTERED (Lower-than-authorized dose administered) and NO ADVERSE EVENT (No adverse event) outcome was unknown.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for INCORRECT DOSE ADMINISTERED (Lower-than-authorized dose administered).    Concomitant product use was not provided by the reporter.  Treatment information was not provided.
both vaccine doses two times; This case was reported by a consumer via interactive digital media and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (1st and 2nd dose received on an unknown date).   On an unknown date, the patient received Shingles vaccine and Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 28-MAR-2022 Reporter's Comment: This case was reported by a consumer via interactive digital media. The reporter asked was it dangerous to have both vaccine doses two times. Additional supportive information:  The patient received both vaccine doses two times, which led to extra dose administered. The follow-up would not possible, as no contact details were available.
One week after injection developed circular, red, itchy , lumpy rash around injection site extending a few inches.
woke up with 100.5 fever, head ache, chills , generalized body aches, stomach ache,  Called my work, they ordered, rapid Covid 19 test, waited for 3 hours and came back negative, but  I'm having  fever 100.3  for two nights and 99.0  at day time, with head ache and stomach ache,
This spontaneous report as received from a licensed practical nurse (LPN) refers to an unspecified number of unspecified patients of unknown age and gender. Medical history and drug allergies were not reported. On unknown dates, the patients were vaccinated with doses of  improperly stored ROTATEQ (lot # K005397, expiration date 29-FEB-2016, route of administration default to oral, dose and frequency were not reported). No adverse effects were reported. Product quality complaint (PQC) was not involved. This is one of several reports received from the same reporter. Additional information has been requested.
Patient started to feel some tightness in her throat about 5 minutes post vaccination. EMS offered medical transport, that was refused and her husband drove her to the nearest medical clinic.
10 minutes after vaccine was administered fever and diarrhea started.  Extra Strength Tylenol was administered every 4 hours. Over the Counter anti-diarrhea  was given.  Highest temperature was 102.8.  Ibuprofen  was given when the fever was highest
Immediate injection site erythema, swelling, pain, x 5 days; fever within 30 minutes, 100.3 x 5 days, spiking to 100.3 x 5 more days (10 days total); body aches, joint pain, fatigue, malaise x 14 days.
High fever body aches shortness breath lost appetite dizziness; High fever body aches shortness breath lost appetite dizziness; High fever body aches shortness breath lost appetite dizziness; High fever body aches shortness breath lost appetite dizziness; High fever body aches shortness breath lost appetite dizziness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (High fever body aches shortness breath lost appetite dizziness), DYSPNOEA (High fever body aches shortness breath lost appetite dizziness), DIZZINESS (High fever body aches shortness breath lost appetite dizziness), DECREASED APPETITE (High fever body aches shortness breath lost appetite dizziness) and PYREXIA (High fever body aches shortness breath lost appetite dizziness) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Sep-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 dosage form. On 07-Sep-2021, the patient experienced PAIN (High fever body aches shortness breath lost appetite dizziness), DYSPNOEA (High fever body aches shortness breath lost appetite dizziness), DIZZINESS (High fever body aches shortness breath lost appetite dizziness), DECREASED APPETITE (High fever body aches shortness breath lost appetite dizziness) and PYREXIA (High fever body aches shortness breath lost appetite dizziness). On 09-Sep-2021, PAIN (High fever body aches shortness breath lost appetite dizziness), DYSPNOEA (High fever body aches shortness breath lost appetite dizziness), DIZZINESS (High fever body aches shortness breath lost appetite dizziness), DECREASED APPETITE (High fever body aches shortness breath lost appetite dizziness) and PYREXIA (High fever body aches shortness breath lost appetite dizziness) had not resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant Medications were provided by the reporter  No Treatment Information were provided by the reporter
Hives; This is a spontaneous report received from a contactable healthcare professional (patient) via COVID-19 Adverse Event.   A 36-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration, administered in left arm on 13Feb2021, at 12:15 (Lot Number: EL9266) as first dose and second dose via an unspecified route of administration, administered in left arm on 06Mar2021 (Lot Number: En6203), each as a single dose for covid-19 immunization, at the age of 36-years old.  The patient's medical history was not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine.  Since the vaccination, the patient had not been tested for COVID-19. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, has the patient has not been tested for COVID-19. Concomitant medications included valacyclovir taken for an unspecified indication, start and stop date were not reported.  The patient experienced hives, which was described by the patient as hives breaking out all over my body on 16Feb2021 with outcome of not recovered.  Details were as follows: Patient reported, it was intense in the about three weeks following the first shot, and it continued after his second shot. Patient reported he had developed hives in areas like armpits, scalp, groin, eyes, lips. No therapeutic measures were not taken for the event. The clinical outcome of hives was not recovered.
01-28: started chest heaviness but bearable , 01-29:intense itchiness all over the body without rash; feeling of closing my airway; went to ED given full dose of benadryl IV, 4 tablets of aspirin and steroids (Dexamethasone) Partial relief of chest heaviness but still there not as intense when i arrived at ED. I was discharged and given prescription of steroids and OTC Benadryl ; 1-30, itchiness starting again, chest heaviness still present despite taking benadryl and steroids 1-31; still with itchiness, chest heaviness, dry cough started
pt recvd vax 22SEP94 & 232SEP94 pt presented in sick call w/either a fever &/or a local or systemic rxn;sxs resolved p/several days;